Idenix Pharma reports positive Phase I/II data of IDX899 to treat HIV-1

Thursday, June 12, 2008; Posted: 08:21 AM

7 Stocks You Need To Know For Tomorrow -- Free Newsletter

BOSTON, Jun 12, 2008 (Thomson Financial via COMTEX) -- IDIX | Quote | Chart | News | PowerRating -- Idenix Pharmaceuticals Inc. Thursday reported positive phase I/II data of IDX899, a non-nucleoside reverse transcriptase inhibitor being developed for the treatment of HIV-1.

Idenix said the data demonstrate potent antiviral activity and favorable safety profile at all tested doses.

"We are very encouraged that the robust antiviral activity observed at 800 mg/day was also achieved by the 400 and 200 mg/day cohorts," Idenix said. "We look forward to evaluating a 100 mg once-daily IDX899 dose in the upcoming weeks."

Shares of Idenix closed Wednesday at $6.17. Casey Logan cl/tk1

Copyright Thomson Financial News Limited 2007. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.

MMMM

For full details on Idenix Pharmaceuticals Inc (IDIX) click here. Idenix Pharmaceuticals Inc (IDIX) has Short Term PowerRatings of 5. Details on Idenix Pharmaceuticals Inc (IDIX) Short Term PowerRatings is available at This Link.

Morning Coffee with TradingMarkets -- Free Newsletter

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.